Navigation Links
Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Date:4/25/2012

HAYWARD, Calif., April 25, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced the completion of dosing in the Company's Phase 2b PEARL-SC study. PEARL-SC (A randomized, double-blind Phase 2b study to evaluate the efficacy, safety, and tolerability of blisibimod administration in subjects with systemic lupus erythematosus) is examining the therapeutic benefit of monthly and weekly subcutaneous administration of blisibimod in systemic lupus erythematosus (SLE) patients.

The primary endpoint of the PEARL-SC study is clinical improvement at 24 weeks in an SLE responder index  (SRI)-- a composite responder index evaluating various patient and physician reported clinical disease activity including a SELENA/SLEDAI* improvement of 5 points or greater, no increase in a physician's global assessment of more than 0.3 points, with no new BILAG A or two or more new BILAG B organ domain scores.

In addition to the primary endpoint analysis, PEARL-SC will provide a series of key secondary subgroup and endpoint analyses which will help guide the design of phase 3 registration studies and further differentiate blisibimod from currently available therapies.  These prospective secondary and exploratory analyses include:

  • Larger improvement in disease activity, as measured by SELENA/SLEDAI reductions of 5, 6, 7 and 8;
  • The percentage of patients achieving the primary endpoint and requiring no increase in steroid dose from baseline;
  • Percentage of patients able to reduce steroid dose and percentage of patients requiring no increase in steroid dose;
  • Time to first SLE flare and first severe SLE flare;
  • Disease activity improvement in lupus patients
    '/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013  An international roster ... Saturday, May 18, in Santa Monica, Calif. ... new lung-sparing therapies for MPM, a rare form of ... affects the pleura, the lining of the chest. ... and Blood Institute, the 3rd Annual International Symposium on ...
(Date:5/24/2013)... 2013  Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ... the Deutsche Bank Health Care Conference to be held ... Adrian Adams , Chief Executive Officer ... the Company and its product pipeline at 12:00 p.m. ... (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) The presentation will ...
(Date:5/24/2013)... The potential of the pulmonary route as ... has been receiving undeniable attention with the recent advances ... crucial formulation considerations for orally inhaled products together with ... in the efficiency of pulmonary delivery, and great strides ... techniques and devices in recent years. With ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2
... and cesarean section trials in conjunction with David ... G. Genecov, MD, FACS, FAAP to begin immediately, ... BIEL), the maker of the ActiPatch(TM), a drug free ... pulse therapy specifically designed to speed healing, today,announced world ...
... CARMEL, Israel, May 28 , - Study ... Non-Invasive,MRgFUS to Those who had Invasive Fibroid Surgery, ... Food and Drug,Administration (FDA) cleared the company to ... safety of the ExAblate(R) 2000 system utilizing,MR-guided Focused ...
Cached Medicine Technology:BioElectronics Announces Major Clinical Trials 2BioElectronics Announces Major Clinical Trials 3BioElectronics Announces Major Clinical Trials 4FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids 2FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids 3FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids 4
(Date:5/25/2013)... 25, 2013 According to an article in ... a Feeling,” nearly 30 million Americans tan indoors each year ... despite knowing the health risks. New research suggests ... addictive effect on the brains of some tanners (Go to ... article so I can’t say that I fully support this ...
(Date:5/25/2013)... 25, 2013 While some will be ... have died serving our Country, many others will simply ... and recklessness. The DUI attorneys at MacGregor & Collins, ... to help keep this weekend’s party-goers out of trouble. ... there were more than 950 fatal alcohol-related collisions and ...
(Date:5/25/2013)... May 25, 2013 Dr. Leslie Gerstman ... procedure FDA-approved to lift skin on the neck, on the ... her practice, Medical Aesthetics. , Ultherapy is a non-surgical procedure ... natural healing process to lift the skin over time. The ... time, to see and then treat the deepest support layers ...
(Date:5/25/2013)... Life science and analytical reagents are ... and create a new substance with the purpose of ... known as biotechnology reagents. Such reagents are significant in ... This market is driven by factors such as expansion ... therapeutics, growth in research and rapid commercialization of such ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 A disorder ... type of peripheral neuropathy. According to neuropathy expert doctor ... it is estimated that the disorder affects almost 50% ... complication arising from Diabetes. The high blood sugar levels ... and patients suffering from it usually tend to have ...
Breaking Medicine News(10 mins):Health News:Sun Damage – Are UV Rays Addictive? 2Health News:Criminal Attorneys Provide Memorial Day Weekend DUI Checklist and Safety Information 2Health News:Criminal Attorneys Provide Memorial Day Weekend DUI Checklist and Safety Information 3Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 2Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 3Health News:Diabetic Neuropathy treatment hits new grounds- Neuracel launches the complete natural treatment 2
... to the list of World Heritage sites Thursday, 34 years ... completed. ,The opera house was one of ... world heritage committee, meeting in Christchurch, New Zealand. ... complex in Shahjahanabad, India, the Iwami Ginzan Silver Mine in ...
... another by swapping their genomes, a move that will accelerate ... on genetics said Thursday. ,Craig Venter, who had ... of his researchers had transplanted the entire genetic code of ... ,The experiment marks the most ambitious attempt yet to re-engineer ...
... World Food Programme (WFP) today announced plans to assist the ... living in communities affected by an ongoing drought. ... the persistence of the drought, and we will work closely ... the lean season," said Tarek Elguindi, WFP Representative in Dili, ...
... ago, Australia was awash in wine. But thanks to the worst drought ... in years and the grape glut is drying up fast. ... the cool-climate town of Orange west of Sydney, the past year has ... frost in November. Then it was so dry we couldn't keep any ...
... tourist district, bamboo scaffolding stretches like a web over a ... ,It's a seemingly unpromising piece of real estate, but ... a massive new complex devoted to Hong Kong's favourite obsession ... handing the territory back to China, sceptics predicted an end ...
... Wiliam's ex-girlfriend Kate Middleton's curvaceous figure has suddenly gone too ... style for her slender but athletic figure, is donning a ... appearances Kate appeared painfully thin, bony and almost flat chested. ... loss is due to the strain following her split with ...
Cached Medicine News:Health News:Replacing a Genome Boosts Race to Develop Designer Bugs: Study 2Health News:Replacing a Genome Boosts Race to Develop Designer Bugs: Study 3Health News:Australian Grape Glut Dries Up as Drought Bites 2Health News:Australian Grape Glut Dries Up as Drought Bites 3Health News:Hong Kong's Shopping Spree Surges On, and on 2Health News:Hong Kong's Shopping Spree Surges On, and on 3
An easy-to-fit high water content spherical soft lens manufactured using cast molding technology, and designed for use in the correction of myopia on a daily wear or extended wear basis....
Hertel exophthalmometer...
1-Day Acuvue brand contact lenses offer the healthiest, most convenient way to wear contact lenses. There's no lens care or messy solutions required, just wear them one day and throw them away....
... connects via a USB port ... computer featuring Windows 2000 or ... the art corneal topography software ... projection and easy alignment reduce ...
Medicine Products: